Envisagenics secures significant Series B investment for groundbreaking RNA technology
TLDR: Envisagenics, a NYC-based biotechnology company, raised Series B funding from existing and new investors, including Bristol Myers Squibb. The company will use the funds to further develop its pipeline of novel